CN101444303A - Dendrobium kudzu eucommia bark functional food - Google Patents
Dendrobium kudzu eucommia bark functional food Download PDFInfo
- Publication number
- CN101444303A CN101444303A CNA2008102337029A CN200810233702A CN101444303A CN 101444303 A CN101444303 A CN 101444303A CN A2008102337029 A CNA2008102337029 A CN A2008102337029A CN 200810233702 A CN200810233702 A CN 200810233702A CN 101444303 A CN101444303 A CN 101444303A
- Authority
- CN
- China
- Prior art keywords
- dendrobium
- kudzu
- eucommia bark
- liver
- extractive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010575 Pueraria lobata Nutrition 0.000 title claims abstract description 48
- 241000208688 Eucommia Species 0.000 title claims abstract description 34
- 241001523681 Dendrobium Species 0.000 title claims abstract description 33
- 235000013376 functional food Nutrition 0.000 title claims abstract description 15
- 241000219781 Pueraria montana var. lobata Species 0.000 title claims abstract 11
- 239000000843 powder Substances 0.000 claims abstract description 8
- 240000004638 Dendrobium nobile Species 0.000 claims description 33
- 239000000284 extract Substances 0.000 claims description 24
- 241000208689 Eucommia ulmoides Species 0.000 claims description 13
- 230000000694 effects Effects 0.000 abstract description 36
- 210000004185 liver Anatomy 0.000 abstract description 29
- 230000036039 immunity Effects 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 22
- 231100000753 hepatic injury Toxicity 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 14
- 206010067125 Liver injury Diseases 0.000 abstract description 11
- 230000036541 health Effects 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 235000013402 health food Nutrition 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 230000004438 eyesight Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000011251 protective drug Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 53
- 244000046146 Pueraria lobata Species 0.000 description 38
- 230000037396 body weight Effects 0.000 description 38
- 239000013642 negative control Substances 0.000 description 34
- 230000002440 hepatic effect Effects 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 27
- 241000700159 Rattus Species 0.000 description 25
- 239000002775 capsule Substances 0.000 description 23
- 230000006870 function Effects 0.000 description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 230000006378 damage Effects 0.000 description 14
- 230000000242 pagocytic effect Effects 0.000 description 13
- 230000001476 alcoholic effect Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 description 7
- 230000007863 steatosis Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical class OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CCEAFOJVRQZWQC-UHFFFAOYSA-N Ddendroxine Natural products CC12C3CCC2CN2CCOC12C1C(C(C)C)C3C(=O)O1 CCEAFOJVRQZWQC-UHFFFAOYSA-N 0.000 description 1
- CCEAFOJVRQZWQC-KFYGABLUSA-N Dendroxine Natural products O=C1O[C@@H]2[C@@H](C(C)C)[C@@H]1[C@H]1[C@]3(C)[C@@H](CN4[C@]23OCC4)CC1 CCEAFOJVRQZWQC-KFYGABLUSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- ZJDOESGVOWAULF-OGJQONSISA-N Geniposidic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=CC[C@@H]2C(C(O)=O)=CO1 ZJDOESGVOWAULF-OGJQONSISA-N 0.000 description 1
- VYAALAFRWREWLA-BVTMAQQCSA-N Geniposidic acid Natural products CCC1=CC[C@H]2[C@@H]1[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C2C(=O)O VYAALAFRWREWLA-BVTMAQQCSA-N 0.000 description 1
- ZJDOESGVOWAULF-UHFFFAOYSA-N Geniposidinsaeure Natural products OC1C(O)C(O)C(CO)OC1OC1C2C(CO)=CCC2C(C(O)=O)=CO1 ZJDOESGVOWAULF-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MAEQVSBPCIMMJF-UHFFFAOYSA-N Nobilonin Natural products CC(C)C1C2C(=O)C3(C)C(CN(C)C)CCC3C1C(=O)O2 MAEQVSBPCIMMJF-UHFFFAOYSA-N 0.000 description 1
- MAEQVSBPCIMMJF-MSZYXCAISA-N Nobilonine Natural products O=C1[C@@]2(C)[C@@H](CN(C)C)CC[C@H]2[C@H]2[C@H](C(C)C)[C@H]1OC2=O MAEQVSBPCIMMJF-MSZYXCAISA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a dendrobium kudzu eucommia bark functional food, and relates to a health food which can offer auxiliary protection for chemical liver injury and improve immunity, in particular to a health care functional food which takes dendrobium as a monarch drug. The food is prepared by uniformly mixing dendrobium powder with granularity no less than 60 meshes, kudzu extractive with eucommia bark extractive, and the dendrobium powder, the kudzu extractive and the eucommia bark extractive are mixed by the following weight fraction: 6-10 parts of dendrobium, 1-3 parts of kudzu extractive, and 1-2 parts of eucommia bark extractive. The functional food is characterized in that a liver-protective drug which is homology of medicine and food, a drug of nourishing yin and varieties which have the function of tonifying yang are organically combined by a reasonable method to produce a health food with remarkable effects. The functional food has the efficacy of protecting liver, improving eyesight, moistening lung, nourishing stomach, and adjusting the equilibrium between yin and yang in human body, and can achieve the effect of notably improving chemical liver injury and a series of symptoms caused by low immunity.
Description
Technical field
The present invention relates to a kind ofly has assistant protection function and strengthens the health food of immunity chemical damage, particularly is the health functional food of monarch drug in a prescription with the stem of noble dendrobium.
Background technology
Liver is important metabolism organ, all plays an important role at aspects such as the absorption of materials such as carbohydrate, lipid, protein, vitamin, hormone, bile, storage, bio-transformation, secretion, drainages.Liver has powerful regeneration and compensatory capacity, can overcome slight or limitation damage and the hepatosis that causes.But many causes of disease can cause the distortion and the necrosis of liver parenchyma, cause cirrhosis and hepatonecrosis.When liver major injury, metabolic capability significantly weaken, serious hepatosis will appear, and further increase the weight of liver failure, and cause the dysfunction of central nervous system and cause hepatic coma.
The factor that causes hepatic injury is a lot, as the excessive absorption of alcohol, the erosion that poison and environmental poisonous substance are produced in drug metabolism etc.Claim that according to the report of U.S. disease prevention and control center portion in 2004 U.S. has 7.5 ten thousand people dead every year because of excessive consumption of alcohol.According to another the report in 2004 of Russian National Commission for Statistics, there are every year 3.7 ten thousand people of surpassing to die from alcoholism.In recent years, the ill crowd of alcoholic liver, fatty liver enlarges day by day among China resident, and ill crowd presents the trend of becoming younger at the age.Now, chemical damages such as alcoholic liver, fatty liver have become a kind of common disease, and it is healthy just seriously to nibble compatriots.The liver problem presses for concern.Exploitation has the functional food of protection hepatic injury, and market potential is huge.
The health care of China is lain across at all times, and the culture of health preserving of heavily health and integration of drinking and medicinal herbs is just arranged from ancient times.Traditional Chinese medicine is the crystallization of the long-term medical practice of the Chinese nation, and it has with modernized health care sees the similar health care idea that communicates.Advantage with traditional Chinese medicine of characteristics such as whole sight, diagnosis and treatment, herbal mixture embodies a concentrated expression of the immunity that can adjust human body in all directions, for the high-quality life style of people provides a kind of strong support means.Doctor trained in Western medicine is said " controlling ", the traditional Chinese medical science is said " accent ", " benefit ", " supporting ", clinical treatment means to enhancing immunity is the injecting immune globulin, but this only only limits to urgent patient's situation, for general population that can normal life, strengthening immunity does not have any clinical medicine can reach better curative effect substantially.For the symptom of the treatment that suffers for want of medical supplies at present, utilize the Chinese medicine exploitation health food of China's integration of drinking and medicinal herbs, be one and well select.
Show that through modern medicine study body immunity lowly is to cause the unsound immediate cause of liver cell, when protecting liver, strengthen body immunity, can strengthen liver function effectively.The present invention fully takes into account this point, utilizes the rare traditional Chinese medicine of medicine-food two-purpose to prepare this functional food, when body immunity is increased, also reaches the effect of liver protecting.
The stem of noble dendrobium: the beginning is stated from Shennong's Herbal, classifies as top gradely, and the successive dynasties book on Chinese herbal medicine is all on the books.The Shennong's Herbal record: " ... it is sweet, flat, nontoxic to distinguish the flavor of.In curing the wound, remove numbness, the therapeutic method to keep the adverse qi flowing downward, the tonifying five zang organs consumptive disease, win thin, reinforcing yin essence.The thick stomach of clothes is made light of one's life by commiting suicide for a long time, prolong life, and longue meat, by skin heat symptoms caused by an exopathgen ， Rush gas, sedate removes frightened ... ".Supplementary Amplifications of the Compendium of Materia Medica (clear Zhao Xuemin): " clearing stomach removes abnormal heat, promotes the production of body fluid, strain, with for tea, Appetizing spleen-tonifying, wind is treated in arresting convulsion, can press down saliva phlegm, relieving summer-heat, sweet fragrant sending down abnormally ascending ".The stem of noble dendrobium that this product adopts is the dry stem of orchid HERBA DENDROBII Dendrobium nobile lindl.; Be " first-selected kind under stem of noble dendrobium item of Chinese pharmacopoeia (version in 2005).HERBA DENDROBII: one one of the Pharmacopoeia of the People's Republic of China (version in 2005) carries:
[nature and flavor with return through] hardship is slightly cold.Return stomach, kidney channel.
[function with cure mainly] reinforcing stomach reg fluid is nourishing Yin and clearing heat.Be used for the moon and hinder body fluid deficiency, the dry polydipsia, food is few retches, abnormal heat after being ill, order is secretly not clear.
The main product ground of HERBA DENDROBII is born on height above sea level 590～3000 meters original remote mountains woods or the crag in Yunnan.The stem of noble dendrobium is oblate cylindricality, long 20～40cm, straight stem 0.4～0.6cm, the long 2.5～3cm of internode.Surface golden yellow or greenish-yellow look have dark longitudinal furrow.The main functional component of HERBA DENDROBII is: dendrobium polysaccharide and stem of noble dendrobium alkaloids.Stem of noble dendrobium alkaloids main component has dendrobine (dendrobine), the stem of noble dendrobium time alkali (nobilonine), stem of noble dendrobium ether alkali (dendroxine), 6-hydroxyl stem of noble dendrobium ether alkali, 4-hydroxyl stem of noble dendrobium ether alkali and methine stem of noble dendrobium element (nobilimethylene) etc.Wherein dendrobium polysaccharide is the roborant main component of the stem of noble dendrobium, can strengthen body's immunity, and has antitumor activity.HERBA DENDROBII is among the people in the locality, Yunnan to be to adopt chip drying or be processed into maple bucket back to sell as rare traditional Chinese medicine all the time, but local common people then only use its dry product or aquatic foods product as tea-drinking.Though its as Chinese medicine and tea-drinking with all being by frying in shallow oil, boil method, the active ingredient of the stem of noble dendrobium can not discharge fully, and fully absorbed by human body, fry in shallow oil, boil by high temperature, the thick polysaccharide of the stem of noble dendrobium becomes oligosaccharides, monose, effect descends, and incorrect and corresponding compatibility of drugs can not be given full play to its effect.
The root of kudzu vine is the dry root of legume pueraria lobata pueraria lobata (Willd.) Ohwi, and the beginning is stated from Shennong's Herbal, and the successive dynasties book on Chinese herbal medicine is all on the books.Except that containing aspects such as prevention cardiovascular and cerebrovascular are had the flavonoids active component of significant curative effect in the root of kudzu vine, also contain the amino acid (lysine, methionine, phenylalanine, isoleucine, leucine etc.) and the trace element (selenium, zinc, manganese, germanium etc.) of needed by human.The root of kudzu vine is to cardiovascular and cerebrovascular, auxiliary antilipemic, hypotensive, auxiliary hyperglycemic, have protective effect, relieve the effect of alcohol, anti-arrhythmia cordis, delay senility, improve learning and memory etc. good effect is all arranged chemical damage.The personnel that are particularly useful for chemical damage.For " Chinese pharmacopoeia (version was an one in 2005) is recorded kind.
The root of kudzu vine: one one of the Pharmacopoeia of the People's Republic of China (version in 2005) carries:
[nature and flavor with return through] are sweet, hot, cold.Distinguish the flavor of sweet, return spleen, stomach warp.
[function with cure mainly] relieving muscles to expel heat promotes the production of body fluid, and promoting eruption rises positive stopping leak.Be used for fever caused by exogenous pathogens headache, stiff nape and back, thirsty, quench one's thirst, measles without adequate eruption, hot dysentery is had loose bowels; The hypertension neck pain.
Folium cortex eucommiae: be the dry leaf of Eucommiaceae plant bark of eucommia Eucommia ulmoides Oliv..The bark of eucommia is the famous and precious tonic Chinese herbal medicine material of China, just is listed in product on the medicine in Shennong's Herbal, Compendium of Material Medica.In recent years, domestic and international many scholars have carried out big quantity research to the chemical composition and the pharmacological action of folium cortex eucommiae, find that the folium cortex eucommiae and the bark of eucommia have similar chemical composition, all have the liver of protecting, strengthen immunity, regulate blood fat, reduce blood sugar, regulate blood pressure, antibiotic, antiviral, suppress pharmacological action such as growth of tumour cell, and delay senility, effects such as beauty face-whitening-nourishing, enriching yin and nourishing kidney, strong muscles and bones.
Xin Xiaoming etc. studies show that, cortex eucommiae total polyoses can obviously suppress the excessive generation that endoxan causes the peroxide MDA (MDA) of the rising of hepatic injury mice serum paddy third transaminase (ALT), millet straw transaminase (AST) and hepatic tissue, impaired hepatic tissue superoxide dismutase (SOD) activity also significantly raises, this helps removing free radical, reduce the peroxidating of membrane lipid, its hepatic injury that endoxan is caused has the good curing effect, for the therapy of combing traditional Chinese and Western medicine of tumour provides experimental basis, both interactional mechanism remain further research.Peng Mijun etc. utilize iridoid content in high performance liquid chromatography-mass spectrometric determination bark of eucommia sample, prove in the leaf, skin of the bark of eucommia to contain similar chemical composition, are mainly iridoids, the plain class of phenylpropyl alcohol, flavonoids etc.Different iridoid compound drug activity differences.Aucubin has the hepatic cholagogic effect, can protect CCl
4The hepatic injury of inducing; That Geniposidic acid then has is anti-aging, promote that collagen is synthetic and improve the cuticula metabolic function of the mouse that grows up; And geniposide has effects such as the interior antithrombotic of body.
Folium cortex eucommiae: one one of the Pharmacopoeia of the People's Republic of China (version in 2005) carries:
[nature and flavor with return through] little suffering, temperature.Return liver, kidney channel.
[function with cure mainly] filling liver kidney, strengthening the bones and muscles.Be used for kidney deficiency and liver, have a dizzy spell, soreness of waist and knee joint, the muscles and bones impotence is soft.
Summary of the invention
Technical problem to be solved by this invention provides a kind of dendrobium kudzu eucommia bark functional food, has the health-care efficacy that significantly protects liver, enhancing immunity, strengthens resistance against diseases, and is without any side effects.
Solving the scheme that technical problem of the present invention adopts is: mixed and formed by granularity 〉=60 purpose stem of noble dendrobium powder, kudzu root extract, eucommia ulmoides extracts, and the ratio of three's mixed weight mark is: 6～10 parts of the stems of noble dendrobium, 1～3 part of kudzu root extract, 1～2 part of eucommia ulmoides extracts.In this prescription, eucommia ulmoides extracts is the extract of folium cortex eucommiae, and the stem of noble dendrobium adopts HERBA DENDROBII, can reach better efficacy, the effect that cost is lower.
Compatibility foundation of the present invention: with the stem of noble dendrobium is monarch drug in a prescription, and assistant is with the root of kudzu vine and folium cortex eucommiae compatibility.Stem of noble dendrobium flavor is sweet, nourishing hepatic yin; Folium cortex eucommiae is returned liver, kidney channel, liver-kidney tonifying; Root of kudzu vine flavor cool in nature is sweet, and clearing heat and promoting fluid is induced sweat.Full side cooperates, and sweet profit is gentle, enriching yin Yiyang, and treating YANG within YIN, then positive that the cloudy biochemistry that helps is infinite, treating YIN within YANG, then YIN matched with sufficient YANG making living things fully vivid; Flat again liver is purged heat, sending up the lucid yang, and the body functional state of transferring person altogether, thereby strengthening vital QI to eliminate pathogenic factors strengthen resistance against diseases, transfer the defense function of human body integral, amount to the purpose of liver protecting.Immunocompromised person and fatiguability person there is good health-care efficacy.
The invention has the beneficial effects as follows: the functional food that adopts the stem of noble dendrobium, the root of kudzu vine, folium cortex eucommiae to produce, easy to use, can give full play to the effect of the stem of noble dendrobium, and it is collaborative mutually with the root of kudzu vine and folium cortex eucommiae, has higher active component, it is more remarkable at the health-care effect of chemical damage person, immunocompromised person's symptom specially, has no side effect.And the significant composition/functional component of food of the present invention is clear and definite, and steady quality meets the requirement of big production.
Aspect the protection of chemical damage: the effect of lipid peroxide catabolite MDA (MDA) content in the hepatic tissue of reduction alcohol damage; The effect of triglyceride (TG) content in the hepatic tissue of reduction alcohol damage; Improve the effect of reduced glutathione (GSH) content in the hepatic tissue; Alleviate the effect of the hepatic tissue steatosis of alcoholic liver injury rat.
Aspect enhancing immunity: promote spleen lymphocyte proliferation, transformation; Enhancing antibody cellulation propagation; Improve serum and melt the sanguinin level; Promote monokaryon-macrophage carbon to clean up the phagocytic activity of function and peritoneal macrophage; Improve NKT (NK) cytoactive.
The specific embodiment
Embodiment 1: medicine of the present invention is made up of following component: (weight proportion)
Main component: 6 parts of the stems of noble dendrobium, 1 part of kudzu root extract, 1 part of eucommia ulmoides extracts.
The preparation method step:
Step 1: stem of noble dendrobium crushed after being dried, mistake 60 mesh sieves, get powder;
Step 2: stem of noble dendrobium powder, kudzu root extract, eucommia ulmoides extracts mix the back and cross 60 mesh sieves, with the amount capsule charge of 0.2g.
Embodiment 2: medicine of the present invention is made up of following component: (weight proportion)
Main component: 6 parts of the stems of noble dendrobium, 2 parts of kudzu root extracts, 2 parts of eucommia ulmoides extracts;
Preparation method step: with embodiment 1.
Embodiment 3: medicine of the present invention is made up of following component: (weight proportion)
Main component: 7 parts of the stems of noble dendrobium, 2 parts of kudzu root extracts, 1 part of eucommia ulmoides extracts;
Preparation method step: with embodiment 1.
Embodiment 4: medicine of the present invention is made up of following component: (weight proportion)
Main component: 7 parts of the stems of noble dendrobium, 1 part of kudzu root extract, 2 parts of eucommia ulmoides extracts.
Preparation method step: with embodiment 1.
The foregoing description is used for chemical damage is had the functional food of assistant protection function and enhancing immunity, through general preparation process, can make multiple formulation, as capsule, tablet, powder, electuary, paste or granule.
The result of function test of the present invention:
The capsule that adopts the foregoing description 1 prescription to make carries out function test and evaluation of test result according to the regulation of Ministry of Public Health's " health food check and assessment technique standard (2003 editions) ".
One, chemical damage there is the assistant protection function result of the test
1, sample is to the influence of rat body weight
Respectively organize rat body weight before and after table 1 test and change (X ± S)
| Dosage group (mg/kg BW) | Number of animals (only) | Before the test (g) | First weekend (g) | Second weekend (g) | The 3rd weekend (g) | The 30th day (g) | Gain in weight (g) |
| 800 | 12 | 257.0±38.2 | 268.1±42.8 | 281.3±43.1 | 298.4±46.3 | 314.2±53.4 | 57.2±22.4 |
| 400 | 12 | 259.2±28.3 | 267.8±32.7 | 280.3±36.1 | 296.8±36.2 | 316.3±41.9 | 57.1±18.2 |
| 200 | 12 | 257.3±25.0 | 267.6±26.3 | 280.0±26.9 | 292.3±24.6 | 306.1±36.8 | 48.8±16.4 |
| The model contrast | 12 | 255.2±29.2 | 272.9±30.2 | 289.8±31.5 | 298.0±32.8 | 328.3±42.2 | 73.2±19.3 |
| Negative control | 12 | 262.7±32.9 | 267.8±29.8 | 289.2±41.8 | 305.3±42.7 | 322.1±42.1 | 59.4±17.0 |
Annotate: in the table between each group comparing difference there are no significant (P〉0.05).
By table 1 as seen, respectively organize the rat body weight unanimity before the test, the gain in weight when respectively organizing the body weight of rat and off-test each week of process of the test compares mutually, and difference does not all have conspicuousness (P〉0.05), shows that this sample does not have obvious influence to the body weight gain of rat.
2, sample is to the influence of hepatic tissue lipid peroxide catabolite MDA (MDA) content of alcoholic liver injury rat
Table 2 is respectively organized liver tissues of rats homogenate MDA (MDA) content (X ± S)
| Dosage group (mg/kg BW) | Number of animals (only) | Hepatic tissue MDA content (nmol/g hepatic tissue) | The P value |
| 800 | 12 | 123.8±27.1 | 0.158 |
| 400 | 12 | 112.5±20.4 | 0.011 |
| 200 | 12 | 117.6±17.8 | 0.026 |
| The model contrast | 12 | 140.0±27.3 | ...... |
| Negative control | 12 | 106.9±15.3 | 0.002 |
Annotate: the P value is each group and model control group statistics relatively in the table
As seen from Table 2, liver decreases the MDA content of model control group liver tissues of rats apparently higher than negative control group, and both difference has highly significant (P＜0.01), illustrate that liver decreases the model establishment.The MDA content of each dosage group liver tissues of rats of sample all is lower than liver and decreases model control group, and in, the difference of low dose group and model control group all has conspicuousness (P＜0.05), shows that this sample has the effect of lipid peroxide content in the hepatic tissue that reduces the alcohol damage.
3, sample is to the influence of hepatic tissue triglycerides (TG) content of alcoholic liver injury rat
Table 3 is respectively organized liver tissues of rats homogenate TG content (X ± S)
| Dosage group (mg/kg BW) | Number of animals (only) | Hepatic tissue TG content (mmol/100g hepatic tissue) | The P value |
| 800 | 12 | 2.43±0.36 | 0.020 |
| 400 | 12 | 2.52±0.42 | 0.020 |
| 200 | 12 | 2.50±0.50 | 0.020 |
| The model contrast | 12 | 4.10±2.06 | .... |
| Negative control | 12 | 1.23±0.93 | 0.020 |
Annotate: the P value is each group and model control group statistics relatively in the table
As seen from Table 3, liver decreases the hepatic tissue TG content of model control group apparently higher than negative control group, and both differences have highly significant (P＜0.01), illustrates that liver decreases model and sets up.The hepatic tissue TG content of each dosage group of sample all is lower than liver and decreases model control group, and all has highly significant (P＜0.05) with the difference of model control group, shows that this sample has the effect of triglyceride (TG) content in the hepatic tissue that reduces the alcohol damage.
4, sample is to the influence of hepatic tissue reduced glutathione (GSH) content of alcoholic liver injury rat
Table 4 is respectively organized liver tissues of rats homogenate GSH content (X ± S)
| Dosage group (mg/kg BW) | Number of animals (only) | Hepatic tissue GSH content (μ mol/g hepatic tissue) | The P value |
| 800 | 12 | 11.4±1.5 | 0.015 |
| 400 | 12 | 11.5±1.2 | 0.008 |
| 200 | 12 | 11.0±1.2 | 0.034 |
| The model contrast | 12 | 9.4±2.1 | .... |
| Negative control | 12 | 11.8±1.8 | 0.007 |
Annotate: the P value is each group and model control group statistics relatively in the table
As seen from Table 4, GSH content significantly is lower than negative control group in the hepatic tissue of liver damage model control group, and both differences have highly significant (P＜0.01), shows that liver decreases model and sets up.The GSH content of each dosage group liver tissues of rats of sample and model control group compare, and difference all has conspicuousness (P＜0.05), shows that this sample is to the GSH content effect of having a significant effect in the hepatic tissue of alcoholic liver injury rat.
5, sample is to the influence of the hepatic tissue steatosis of alcoholic liver injury rat
Table 5 is respectively organized liver tissues of rats steatosis check result (X ± S)
| Dosage group (mg/kg BW) | Number of animals (only) | Tissue fat sex change scoring | The P value |
| 800 | 12 | 206.1±65.5 | 0.000 |
| 400 | 12 | 137.6±96.8 | 0.000 |
| 200 | 12 | 129.4±53.1 | 0.000 |
| The model contrast | 12 | 76.8±63.6 | .... |
| Negative control | 12 | 268.1±7.17 | 0.000 |
Annotate: the P value is each group and model control group statistics relatively in the table
As seen from Table 5, the hepatic tissue steatosis score value that liver decreases the model control group rat is higher than negative control group, and both differences have highly significant (P＜0.01), shows that liver decreases model and sets up.Each dosage group liver tissues of rats steatosis score value of sample all is lower than liver and decreases model control group, and has conspicuousness (P＜0.01) with the difference of model control group, shows that this sample has the effect of the hepatic tissue steatosis that alleviates the alcoholic liver injury rat.
Brief summary: per os gives the dendrobium kudzu eucommia bark capsule of rat 200mg/kg BW, 400mg/kg BW, 800mg/kg BW (be equivalent to human body and recommend 5,10,20 times of consumptions) dosage, give rat continuous irrigation stomach 30 days, can significantly reduce MDA (MDA), triglycerides (TG) content in the liver tissues of rats that alcoholic liver decreases model and improve reduced glutathione (GSH) content in the hepatic tissue, alleviate hepatic tissue steatosis degree, the body weight of rat is not had obvious influence.This shows that this sample has has the assistant protection function effect to alcoholic liver injury.Can prove that from above-mentioned model this sample has assistant protection function to hepatic injury.
Two, strengthen the function test result of immunity
1, sample is to the influence of mouse body weight
Table 1 dendrobium kudzu eucommia bark capsule enhancing immunity function test mice body weight (x ± s)
Immunity I group (the mouse spleen lymphocyte transformation experiment that ConA induces, NK cytoactive are measured)
| Dosage group (mg/kg BW) | Number of animals (only) | Initial body weight (g) | Body weight in mid-term (g) | Body weight in latter stage (g) | Weightening finish (g) |
| 800 | 12 | 20.7±1.0 | 29.2±1.6 | 35.3±2.1 | 14.6±2.1 |
| 400 | 12 | 20.5±1.0 | 28.9±1.8 | 35.1±1.9 | 14.5±2.2 |
| 200 | 12 | 20.8±0.9 | 29.2±1.6 | 35.4±2.4 | 15.1±2.1 |
| Negative control | 12 | 20.7±1.0 | 29.3±1.6 | 35.9±2.4 | 15.3±2.3 |
Annotate: each dosage group experiment is initial, mouse body weight and the weightening finish and control group comparison in mid-term and latter stage, there are no significant for difference (P〉0.05).
Table 2 dendrobium kudzu eucommia bark capsule enhancing immunity function test mice body weight (x ± s)
Immunity II group (carbon is cleaned up experiment)
| Dosage group (mg/kg BW) | Number of animals (only) | Initial body weight (g) | Body weight in mid-term (g) | Body weight in latter stage (g) | Weightening finish (g) |
| 800 | 12 | 20.1±0.6 | 29.2±1.6 | 34.8±1.4 | 14.7±1.8 |
| 400 | 12 | 20.2±0.8 | 28.9±1.9 | 35.3±1.6 | 14.8±1.2 |
| 200 | 12 | 20.1±0.8 | 29.2±2.2 | 34.4±2.2 | 14.6±2.2 |
| Negative control | 12 | 20.2±0.6 | 29.3±2.0 | 35.4±2.0 | 14.1±1.7 |
Immunity III group (dirty/the body ratio measurement, serum hemolysin is measured and the antibody-producting cell number is measured)
| Dosage group (mg/kg BW) | Number of animals (only) | Initial body weight (g) | Body weight in mid-term (g) | Body weight in latter stage (g) | Weightening finish (g) |
| 800 | 12 | 20.1±0.6 | 27.2±1.6 | 34.3±1.4 | 14.5±2.1 |
| 400 | 12 | 20.2±0.8 | 27.9±1.4 | 35.1±1.6 | 14.4±1.5 |
| 200 | 12 | 20.1±0.8 | 28.2±1.6 | 34.4±2.2 | 15.1±2.1 |
| Negative control | 12 | 20.2±0.6 | 28.3±2.6 | 35.9±2.0 | 14.6±1.7 |
Immunity IV group (delayed allergy experiment)
| Dosage group (mg/kg BW) | Number of animals (only) | Initial body weight (g) | Body weight in mid-term (g) | Body weight in latter stage (g) | Weightening finish (g) |
| 800 | 12 | 20.2±0.4 | 28.9±1.5 | 34.7±2.3 | 14.5±2.3 |
| 400 | 12 | 20.3±0.6 | 29.1±1.1 | 34.8±1.6 | 14.6±1.7 |
| 200 | 12 | 20.3±0.8 | 29.2±0.8 | 34.8±1.5 | 14.5±1.3 |
| Negative control | 12 | 20.4±1.8 | 28.3±1.2 | 35.6±1.8 | 15.3±1.8 |
Immunity V group (Turnover of Mouse Peritoneal Macrophages is engulfed the chicken red blood cell experiment)
| Dosage group (mg/kg BW) | Number of animals (only) | Initial body weight (g) | Body weight in mid-term (g) | Body weight in latter stage (g) | Weightening finish (g) |
| 800 | 12 | 20.4±1.0 | 28.3±1.2 | 34.9±2.0 | 14.5±2.0 |
| 400 | 12 | 20.4±1.0 | 29.3±2.1 | 35.9±2.1 | 15.5±2.0 |
| 200 | 12 | 20.3±0.9 | 28.5±1.6 | 34.4±2.3 | 14.1±2.4 |
| Negative control | 12 | 20.5±1.0 | 29.0±2.3 | 34.9±2.2 | 14.4±1.8 |
Annotate: each dosage group experiment is initial, mouse body weight and the weightening finish and control group comparison in mid-term and latter stage, there are no significant for difference (P〉0.05).
By table 1, table 2 as seen, test between first, as to test mid-term, experiment each dosage group of sample in latter stage mouse body weight and experimental session weight of mice and negative control group and compare, there are no significant for difference (P〉0.05), show that this sample does not have obvious influence to the body weight gain of mouse.
2, sample is to the influence of mouse immune organ internal organs/body weight ratio
Immune organ internal organs/body weight the ratio of table 3 dendrobium kudzu eucommia bark capsule enhancing immunity function test mice (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | Number thymus gland/body weight (%) | The P value | Spleen/body weight (%) | The P value |
| 800 | 12 | 0.273±0.034 | 1.000 | 0.443±0.044 | 0.815 |
| 400 | 12 | 0.256±0.024 | 0.589 | 0.430±0.058 | 1.000 |
| 200 | 12 | 0.271±0.065 | 0.995 | 0.437±0.044 | 0.967 |
| Negative control | 12 | 0.274±0.027 | --- | 0.430±0.024 | --- |
By table 3 as seen, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, thymus gland/body weight of mouse and spleen/body weight ratio and negative control group compare, and difference that there are no significant (P〉0.05), show that this sample does not have obvious influence to the immune organ weight of mouse.
3, sample is to the influence of the cellular immunity of mouse
3.1 the influence of the mouse spleen lymphocyte conversion capability that sample is induced ConA
The mouse lymphocyte transformation experiment result of table 4 dendrobium kudzu eucommia bark capsule (the official's internal organs/body weight ratio of x ± s) (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | Lymphopoiesis ability (OD value) | The P value |
| 800 | 12 | 1.606±1.301 | 0.001 |
| 400 | 12 | 0.768±0.206 | 0.431 |
| 200 | 12 | 0.550±0.161 | 0.918 |
| Negative control | 12 | 0.407±0.308 | --- |
As seen from Table 4, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the lymphocyte transformation ability of high dose group mouse is apparently higher than negative control group, difference has conspicuousness (P＜0.01), shows that this sample has the lymphopoiesis that promotes mouse, the effect of conversion capability.
3.2 sample is to the influence of mouse delayed allergy (DTH)
Mouse delayed allergy (DTH) experimental result of table 5 dendrobium kudzu eucommia bark capsule (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | Left and right sides auricle weight difference (mg) | The P value |
| 800 | 12 | 11.63±2.26 | 0.089 |
| 400 | 12 | 11.25±2.74 | 0.197 |
| 200 | 12 | 10.50±2.34 | 0.639 |
| Negative control | 12 | 9.57±1.87 | --- |
As seen from Table 5, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the left and right sides auricle weight difference of high, middle low dose group mouse is higher than negative control group, but there was no significant difference (P〉0.05), show that this sample does not promote the effect of delayed allergy.
4, sample is to the influence of the humoral immunity of mouse
4.1 sample is to the influence of the antibody-producting cell number of mouse
As seen from Table 6, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the antibody-producting cell number of high dose group mouse is higher than negative control group, and two groups of differences have conspicuousness (P＜0.05), shows that this sample has the effect that promotes mouse antibodies cellulation propagation.
The antibody-producting cell test experience result of table 6 dendrobium kudzu eucommia bark capsule (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | Hemolysis plaque number (1 * 10 3/ full spleen) | The P value |
| 800 | 12 | 227.50±26.65 | 0.042 |
| 400 | 12 | 216.83±21.41 | 0.338 |
| 200 | 12 | 210.25±29.45 | 0.755 |
| Negative control | 12 | 202.00±30.00 | --- |
4.2 sample is to the influence of mice serum hemolysin
The mouse hemolysin measurement result of table 7 dendrobium kudzu eucommia bark capsule (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | The antibody product | The P value |
| 800 | 12 | 166.25±18.96 | 0.001 |
| 400 | 12 | 161.75±16.35 | 0.002 |
| 200 | 12 | 154.33±20.29 | 0.029 |
| Negative control | 12 | 134.83±15.87 | --- |
As seen from Table 7, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the antibody product of high, medium and low dosage group mouse is higher than negative control group, and all have conspicuousness (P＜0.01 and P＜0.05 respectively) with the difference of negative control group, show that this sample has the effect of the serum hemolysin level that improves mouse.
5, sample is to the influence of monokaryon-macrophage phagocytic function of mouse
5.1 sample is to the influence that monokaryon-macrophage carbon is cleaned up of mouse
The mouse carbon of table 8 dendrobium kudzu eucommia bark capsule is cleaned up experimental result (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | Phagocytic index | The P value |
| 800 | 12 | 10.72±1.41 | 0.001 |
| 400 | 12 | 9.95±1.53 | 0.007 |
| 200 | 12 | 8.61±1.60 | 0.675 |
| Negative control | 12 | 8.06±1.22 | --- |
As seen from Table 8, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the phagocytic index of high, middle dosage group mouse is higher than negative control group, have conspicuousness (P＜0.01) with the difference of negative control group, show that this sample has and promote monokaryon-macrophage carbon of mouse to clean up the effect of function.
5.2 sample is engulfed the influence of chicken red blood cell ability to the peritoneal macrophage of mouse
The Turnover of Mouse Peritoneal Macrophages of table 9 dendrobium kudzu eucommia bark capsule is engulfed chicken red blood cell experimental result (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | Phagocytic rate (%) | The phagocytic index data transaction | The P value | Phagocytic index | The P value |
| 800 | 12 | 47.42±13.17 | 0.762±0.142 | 0.001 | 0.854±0.394 | 0.001 |
| 400 | 12 | 38.42±9.73 | 0.667±0.100 | 0.007 | 0.756±0.284 | 0.011 |
| 200 | 12 | 28.33±9.12 | 0.559±0.096 | 0.760 | 0.514±0.192 | 0.637 |
| Negative control | 12 | 24.92±8.98 | 0.519±0.098 | --- | 0.398±0.239 | --- |
As seen from Table 9, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the peritoneal macrophage of each dosage group mouse of sample all is higher than negative control group to the phagocytic rate and the phagocytic index of chicken red blood cell, the difference of the phagocytic rate of height wherein, middle dosage group and phagocytic index and control group has conspicuousness (P＜0.01 or P＜0.05), shows that this sample has the effect of the peritoneal macrophage phagocytic function that promotes mouse.
6, sample is to the influence of the NK cytoactive of mouse
The NK cells in mice determination of activity result of table 10 dendrobium kudzu eucommia bark capsule (x ± s)
| Dosage group (mg/kg BW) | Number of animals (only) | NK cytoactive (%) | NK cytoactive data transaction | The P value |
| 800 | 12 | 59.61±13.10 | 0.887±0.143 | 0.001 |
| 400 | 12 | 41.37±10.23 | 0.697±0.104 | 0.001 |
| 200 | 12 | 28.81±8.17 | 0.562±0.094 | 0.003 |
| Negative control | 12 | 14.20±12.86 | 0.360±0.174 | --- |
As seen from Table 10, per os gives the dendrobium kudzu eucommia bark capsule 30 days of mouse various dose, the NK cytoactive of each dosage group mouse of sample all is higher than negative control group, and the difference of each dosage group and negative control group has highly significant (P＜0.01), shows that this sample has the effect of the NK cytoactive that improves mouse.
Brief summary: per os gives mouse 200mg/kg BW, 400mg/kg BW, 800mg/kg BW (is equivalent to human body and recommends consumption 5,10,20 times) the dendrobium kudzu eucommia bark capsule of dosage 30 days, can promote the spleen lymphocyte proliferation of mouse, transformation, promote the antibody-producting cell propagation of mouse, improve the serum hemolysin level of mouse, promote monokaryon-macrophage carbon of mouse to clean up the phagocytic activity of function and peritoneal macrophage, improve the NK cytoactive of mouse, body weight gain to mouse, thymus gland/body weight ratio, spleen/body weight ratio does not have obvious influence, points out this sample to have the function that strengthens immunity.
Claims (3)
1, a kind of dendrobium kudzu eucommia bark functional food is characterized in that: mixed by granularity 〉=60 purpose stem of noble dendrobium powder and kudzu root extract and eucommia ulmoides extracts and form.
2, dendrobium kudzu eucommia bark functional food according to claim 1 is characterized in that: the ratio of the mixed weight mark of stem of noble dendrobium powder, kudzu root extract, eucommia ulmoides extracts is: 6～10 parts of the stems of noble dendrobium, 1～3 part of kudzu root extract, 1～2 part of eucommia ulmoides extracts.
3, according to right 1 or 2 described dendrobium kudzu eucommia bark functional foods, it is characterized in that: eucommia ulmoides extracts is the extract of folium cortex eucommiae, and the stem of noble dendrobium adopts HERBA DENDROBII.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102337029A CN101444303B (en) | 2008-12-10 | 2008-12-10 | Dendrobium kudzu eucommia bark functional food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102337029A CN101444303B (en) | 2008-12-10 | 2008-12-10 | Dendrobium kudzu eucommia bark functional food |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101444303A true CN101444303A (en) | 2009-06-03 |
| CN101444303B CN101444303B (en) | 2013-04-03 |
Family
ID=40740416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102337029A Expired - Fee Related CN101444303B (en) | 2008-12-10 | 2008-12-10 | Dendrobium kudzu eucommia bark functional food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101444303B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810330A (en) * | 2010-04-19 | 2010-08-25 | 奉化益珍海藻科技有限公司 | Enteromorpha clathrata-dendrobium refined flour |
| CN102318823A (en) * | 2011-10-07 | 2012-01-18 | 刘和勇 | Dendrobium nobile nutritive powder |
| CN101653249B (en) * | 2009-09-03 | 2012-08-08 | 陶国闻 | Functional food capable of lowering blood sugar and enhancing immunity |
| CN103238798A (en) * | 2013-05-17 | 2013-08-14 | 绍兴儒林生物科技有限公司 | Dendrobium nutrient tablet and preparation method |
| CN104509620A (en) * | 2014-12-11 | 2015-04-15 | 罗生芳 | Herbal tea containing eucommia folium and preparation method thereof |
| CN104872713A (en) * | 2015-05-27 | 2015-09-02 | 安徽先知缘食品有限公司 | Dendrobium nobile and kudzu vine root duck gizzard and preparation method thereof |
| CN108936630A (en) * | 2018-08-07 | 2018-12-07 | 九仙尊霍山石斛股份有限公司 | A kind of Dendrobidium huoshanness turmeric radix puerariae capsule and preparation method |
-
2008
- 2008-12-10 CN CN2008102337029A patent/CN101444303B/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653249B (en) * | 2009-09-03 | 2012-08-08 | 陶国闻 | Functional food capable of lowering blood sugar and enhancing immunity |
| CN101810330A (en) * | 2010-04-19 | 2010-08-25 | 奉化益珍海藻科技有限公司 | Enteromorpha clathrata-dendrobium refined flour |
| CN101810330B (en) * | 2010-04-19 | 2012-09-19 | 奉化益珍海藻科技有限公司 | Manufacture method of enteromorpha clathrata-dendrobium refined flour |
| CN102318823A (en) * | 2011-10-07 | 2012-01-18 | 刘和勇 | Dendrobium nobile nutritive powder |
| CN102318823B (en) * | 2011-10-07 | 2012-07-25 | 刘和勇 | Dendrobium nobile nutritive powder |
| CN103238798A (en) * | 2013-05-17 | 2013-08-14 | 绍兴儒林生物科技有限公司 | Dendrobium nutrient tablet and preparation method |
| CN103238798B (en) * | 2013-05-17 | 2015-04-22 | 绍兴儒林生物科技有限公司 | Dendrobium nutrient tablet and preparation method |
| CN104509620A (en) * | 2014-12-11 | 2015-04-15 | 罗生芳 | Herbal tea containing eucommia folium and preparation method thereof |
| CN104872713A (en) * | 2015-05-27 | 2015-09-02 | 安徽先知缘食品有限公司 | Dendrobium nobile and kudzu vine root duck gizzard and preparation method thereof |
| CN108936630A (en) * | 2018-08-07 | 2018-12-07 | 九仙尊霍山石斛股份有限公司 | A kind of Dendrobidium huoshanness turmeric radix puerariae capsule and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101444303B (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435775B (en) | A kind of Traditional Chinese medicinal health-care wine and preparation method thereof | |
| CN102907604B (en) | Health-care product having effects of reducing blood sugar and pressure, losing weight, relaxing bowels, maintaining beauty and resisting fatigue and production process thereof | |
| CN101444303B (en) | Dendrobium kudzu eucommia bark functional food | |
| CN106666312A (en) | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof | |
| CN103099089A (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
| CN105029605A (en) | Preparation method of jasmine health maintenance enzyme beverage | |
| CN109222100A (en) | A kind of ginseng Cordyceps militaris composition, ginseng Cordyceps militaris pressed candy and preparation method thereof | |
| CN107156828A (en) | A kind of full nutrition formula food suitable for patients with inflammatory bowel | |
| CN106244371A (en) | A kind of blood sugar lowering Rhizoma Polygonati grape health care wine and production technology thereof | |
| CN102366595A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN105010669A (en) | Refreshing and moistening health-care jasmine flower tea and production method thereof | |
| CN101305801A (en) | Dendrobium nobile American ginseng capsule | |
| CN101946895B (en) | Functional food taking loach as main material and preparation method thereof | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
| CN101708306B (en) | Chinese medicinal composition for treating gastropathy and preparation method thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN105685317A (en) | Selenium-rich Fructus Cannabis tea and preparation method thereof | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN104544084B (en) | A kind of health food for diabetics | |
| CN104721592B (en) | Rhizoma Gastrodiae honey film-making and preparation method | |
| CN106701410A (en) | Healthcare wine capable of strengthening stomach and tonifying qi and production method thereof | |
| CN106860814B (en) | Health food composition for improving female frequent micturition and urinary incontinence and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG JING Free format text: FORMER OWNER: TAO GUOWEN Effective date: 20141119 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Jing Inventor before: Tao Guowen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650106 KUNMING, YUNNAN PROVINCE TO: 650000 KUNMING, YUNNAN PROVINCE Free format text: CORRECT: INVENTOR; FROM: TAO GUOWEN TO: WANG JING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141119 Address after: 650000 No. 7, Donghua 30, Donghua District, Guandu District, Yunnan, Kunming Patentee after: Wang Jing Address before: 650106 Yunnan city of Kunming province high tech Zone Haiyuan Road No. 6 building nine floor high tech investment Patentee before: Tao Guowen |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130403 Termination date: 20191210 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |